该基金股票持仓前十分别为：恒瑞医药、科伦药业、海思科、百利天恒、新诺威、泽璟制药-U、信立 泰、热景生物、益方生物-U、诺诚健华-U。前十持仓占比合计68.66%。 金融界2025年8月3日消息，汇添富医疗服务灵活配置混合A(001417) 最新净值1.9610元，该基金近一周 收益率4.14%，近3个月收益率26.03%，今年来收益率62.87%。 来源：金融界 汇添富医疗服务灵活配置混合A基金成立于2015年6月18日，基金经理张韡，截至2025年6月30日，汇添 富医疗服务灵活配置混合A规模29.15亿元。 ...

Group 1 - The core viewpoint of the article highlights the performance of the Fortune Healthcare Industry Mixed A Fund, which has shown significant returns over various time frames [1] - As of August 3, 2025, the fund's latest net value is 4.0440 yuan, with a weekly return of 4.42%, a three-month return of 27.01%, and a year-to-date return of 44.58% [1] - The fund was established on August 7, 2013, and as of June 30, 2025, it has a total scale of 972 million yuan [1] Group 2 - The top ten stock holdings of the fund include companies such as Baillie Gifford, Zai Lab, Hotgen Biotech, and Innovent Biologics, with the top ten holdings accounting for a total of 60.20% of the fund's portfolio [1]

易方达医疗保健行业混合C基金成立于2023年10月18日，基金经理杨桢霄，截至2025年6月30日，易方 达医疗保健行业混合C规模3.64亿元。 该基金股票持仓前十分别为：恒瑞医药、热景生物、信立泰、百济神州-U、海思科、诺诚健华-U、一 品红、科伦药业、舒泰神、百利天恒。前十持仓占比合计58.14%。 金融界2025年8月3日消息，易方达医疗保健行业混合C(019020) 最新净值4.6500元，该基金近一周收益 率6.58%，近3个月收益率35.81%，今年来收益率53.57%。 来源：金融界 ...

金融界2025年8月3日消息，富国精准医疗混合C(018209) 最新净值3.5843元，该基金近一周收益率 4.27%，近3个月收益率27.23%，今年来收益率62.42%。 来源：金融界 富国精准医疗混合C基金成立于2023年4月27日，基金经理赵伟，截至2025年6月30日，富国精准医疗混 合C规模9.49亿元。 该基金股票持仓前十分别为：惠泰医疗、海思科、百利天恒、科伦药业、泽璟制药-U、诺诚健华-U、 信立泰、澳华内镜、百济神州-U、悦康药业。前十持仓占比合计70.14%。 ...

Market Performance - The Shanghai Composite Index reached a peak of 3636 points in July, marking a monthly increase of 3.74%, the largest single-month gain of the year [1] - Active equity funds focused on innovative pharmaceuticals have seen significant returns, with five products doubling their returns year-to-date as of July 31 [1] Fund Performance - The top-performing mixed fund, Changcheng Pharmaceutical Industry Select, achieved a year-to-date return of 127.05%, leading the mixed fund performance rankings [2][3] - Other notable mixed funds include Zhongyin Hong Kong Stock Connect Pharmaceutical and Yongying Pharmaceutical Innovation, both exceeding 100% year-to-date returns [2] Fund Manager Insights - The Changcheng Pharmaceutical Industry Select fund, managed by Liang Furui, has a diversified portfolio that includes innovative drugs, traditional Chinese medicine, and diagnostic reagents [3] - Liang Furui anticipates that the innovative drug sector will continue to grow, focusing on overseas licensing and domestic sales expansion in the third quarter [4] Sector Analysis - The mixed fund Yongying Technology Select, representing the technology theme, recorded a year-to-date increase of 94%, primarily investing in leading optical module companies [6] - The stock fund Hua'an Pharmaceutical Bio topped the stock fund performance list with a year-to-date return of 105%, followed by Jiasheng Mutual Selection and Fortune Pharmaceutical Innovation, both exceeding 90% [9] Underperforming Funds - The mixed fund Qianhai Kaiyuan Artificial Intelligence experienced a significant decline, with a year-to-date drop of 19.15%, leading the underperforming fund list [7][8] - Other mixed funds with notable declines include Xinyuan Consumer Selection and Vanguard Gathering, with decreases of 17% and 13%, respectively [8] Investment Strategies - The fund manager Jin Zicai of the Caitong Integrated Circuit Industry fund reported a monthly return of over 31% in July, indicating a turnaround after a poor performance earlier in the year [10][11] - Jin Zicai's strategy includes significant adjustments in the second quarter, focusing on stocks in the optical module and PCB sectors, which are expected to benefit from ongoing demand in overseas markets [12]

Group 1 - The core viewpoint of the article highlights the resurgence of the innovative drug sector, with significant stock price increases for companies like Weikang Pharmaceutical and Yuekang Pharmaceutical, indicating a positive market sentiment [1] - The pharmaceutical sector is experiencing a shift in policy attitudes, with optimization of centralized procurement rules, which is expected to benefit the industry [1] - After years of R&D investment, the pharmaceutical pipeline is entering a harvest phase, and there is an accelerating trend of overseas business development (BD) in the industry, showcasing the global competitiveness of China's innovative drugs [1] Group 2 - Zhongyin Securities suggests focusing on companies that are entering the realization or volume expansion phase, particularly those with overseas capabilities, such as Innovent Biologics, CanSino Biologics, and Eucure Biopharma [1] - The upcoming 2024 national medical insurance negotiations are anticipated to further impact the innovative drug field positively, creating opportunities for valuation reconstruction in the pharmaceutical sector [1]

相关事件 隔夜美股三大指数收跌，中概指数涨0.66%。港股三大指数小幅低开，恒指跌0.12%，国指跌0.14%，恒 生科技指数跌0.09%。盘面上，大型科技股涨跌不一，其中，阿里巴巴涨近2%，快手涨1.3%，百度涨 1%，腾讯小幅上涨，小米、美团飘绿；国际油价下跌，石油股走低，中国石油化工跌超2%；昨日走强 的濠赌股普跌，新濠国际发展跌近6%，创新药概念股部分下跌，百济神州、诺诚健华、三生制药、药 明康德均有跌幅，脑机概念股南京熊猫电子跌近5%。另一方面，软件类股、直播概念股、内房股与物 管股多数上涨，东方甄选涨近3%，蔚来高开近9%领衔汽车股上涨，乐道L90正式上市。(格隆汇) 港股收评：恒生指数涨0.62%！光伏、钢铁成亮点，军工、芯片股表现疲软 港股收评：恒生指数跌 0.56%！内房股、汽车股低迷，黄金股逆势爆发 港股收评：三大指数涨跌不一，恒生科技指数涨 0.56%，医药、军工、汽车大涨 港股收评：恒指再度失守24000，恒生科技指数跌0.33%，医药、芯片、 券商大涨居前 ...

Market Overview - US stock indices closed lower, while the China concept index rose by 0.66% [1] - Hong Kong stock indices opened slightly lower, with the Hang Seng Index down 0.12%, the National Index down 0.14%, and the Hang Seng Tech Index down 0.09% [1] Company Performance - Major tech stocks showed mixed performance; Alibaba rose nearly 2%, Kuaishou increased by 1.3%, and Baidu gained 1%, while Tencent saw a slight increase [1] - Xiaomi and Meituan experienced declines [1] Sector Performance - International oil prices fell, leading to a decline in oil stocks, with China Petroleum & Chemical down over 2% [1] - Gaming stocks, which had performed well previously, saw a broad decline, with New Macau International Development dropping nearly 6% [1] - Innovative drug concept stocks experienced declines, including Baijiahe, Nuocheng Jianhua, Sanofi, and WuXi AppTec [1] - Brain-computer interface stocks, such as Nanjing Panda Electronics, fell nearly 5% [1] - Conversely, software stocks, live streaming concept stocks, domestic property stocks, and property management stocks mostly rose, with Dongfang Zhenxuan increasing nearly 3% [1]

7月31日，多只前期表现强势的创新药ETF有所回调。拉长时间来看，创新药主题ETF仍然是近期全市 场回报率较高的一类ETF产品。Wind数据显示，截至7月31日，来自华泰柏瑞基金、万家基金、汇添富 基金旗下的港股创新药主题ETF今年以来回报率均超过100%。 有业内人士认为，下一阶段创新药领域有望迎来"1-10"的爆发阶段，更多创新药产品在国内上市放量， 同时海外市场会出现代表性新药。相关板块投资正经历从"防御性配置"向"进攻性赛道"的范式转换。但 是，创新药板块的普涨行情不可能持续，后续的超额收益取决于投资者的认知和对信息的解读能力，真 正有创新能力的创新药企才能吸引到资金的青睐。 多只创新药"翻倍基"涌现 医药板块在经过数年的调整之后，今年以来表现不俗。以7月29日的数据为例，创新药板块行情火热， 多只相关主题基金单日净值增长率超4%。Wind数据显示，当日已有6只ETF今年以来涨幅超过100%， 均为创新药主题产品。公开资料显示，这6只ETF来自汇添富基金、华泰柏瑞基金、景顺长城基金、广 发基金、银华基金、万家基金6家公募机构。 在7月30日和7月31日，创新药板块出现分化，部分创新药主题ETF出现一定 ...

Group 1 - The core viewpoint is that the innovative drug sector is experiencing a significant growth phase, with expectations for a "1-10" explosive stage as more innovative drugs are launched domestically and representative new drugs appear in overseas markets [1][3] - Innovative drug ETFs have shown strong performance, with several funds achieving over 100% returns this year, indicating a robust interest in this sector [1][2] - The investment landscape is shifting from defensive to offensive strategies, with innovative drugs being viewed as a growth line that can withstand market cycles [3][4] Group 2 - Fund managers express optimism about the potential for excess returns in the innovative drug sector, anticipating a long harvest period starting from 2025 [3][4] - The innovative drug sector is characterized by high investment, long cycles, and intense competition, which may lead to valuation bubbles if not carefully managed [5][6] - Evaluating innovative drug companies should focus on global competitiveness and domestic commercialization capabilities, with an emphasis on strategic partnerships and market positioning [7]